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Abstract
Coronaviruses infect animals and humans causing a wide range of diseases. The diversity
of coronaviruses in many mammalian species is contributed by relatively high mutation and
recombination rates during replication. This dynamic nature of coronaviruses may facilitate
cross-species transmission and shifts in tissue or cell tropism in a host, resulting in substan-
tial change in virulence. Feline enteric coronavirus (FECV) causes inapparent or mild enteri-
tis in cats, but a highly fatal disease, called feline infectious peritonitis (FIP), can arise
through mutation of FECV to FIP virus (FIPV). The pathogenesis of FIP is intimately associ-
ated with immune responses and involves depletion of T cells, features shared by some
other coronaviruses like Severe Acute Respiratory Syndrome Coronavirus. The increasing
risks of highly virulent coronavirus infections in humans or animals call for effective antiviral
drugs, but no such measures are yet available. Previously, we have reported the inhibitors
that target 3C-like protease (3CLpro) with broad-spectrum activity against important human
and animal coronaviruses. Here, we evaluated the therapeutic efficacy of our 3CLpro inhibi-
tor in laboratory cats with FIP. Experimental FIP is 100% fatal once certain clinical and labo-
ratory signs become apparent. We found that antiviral treatment led to full recovery of cats
when treatment was started at a stage of disease that would be otherwise fatal if left
untreated. Antiviral treatment was associated with a rapid improvement in fever, ascites,
lymphopenia and gross signs of illness and cats returned to normal health within 20 days or
less of treatment. Significant reduction in viral titers was also observed in cats. These
results indicate that continuous virus replication is required for progression of immune-medi-
ated inflammatory disease of FIP. These findings may provide important insights into devis-
ing therapeutic strategies and selection of antiviral compounds for further development for
important coronaviruses in animals and humans.
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Author Summary
Coronaviruses are important pathogens in humans and animals. Although some coronavi-
ruses can cause severe illness in humans and animals with considerable fatality, there is no
antiviral drugs available for coronavirus infections. Feline infectious peritonitis (FIP),
caused by virulent feline coronavirus, is the leading infectious cause of death in young cats,
and also threatens endangered captive wild cats. We have previously reported series of
small molecule protease inhibitors with broad-spectrum activity against important human
and animal coronaviruses. In this report, we provide, for the first time, experimental evi-
dence of efficacy and safety of one of the protease inhibitors in laboratory cats with experi-
mentally induced FIP. These findings suggest that direct inhibition of virus replication by
a protease inhibitor can be devised as a viable treatment option for coronavirus infection
and our protease inhibitor has a potential to be developed into an effective therapeutic
agent for FIP.
Introduction
Coronaviruses comprise a large family of RNA viruses that infect a wide variety of mammalian
and avian hosts causing a broad spectrum of diseases. Coronaviruses have a single-stranded,
positive-sense RNA genome and are classified into four genera of alpha-, beta-, gamma-, and
deltacoronaviruses [1]. Coronaviruses are prone to mutation and recombination during repli-
cation and this propensity has contributed to the existing diversity of coronaviruses [2, 3]. Sud-
den emergence of new coronaviruses transmitted from animal hosts, Severe Acute Respiratory
Syndrome Coronavirus (SARS-CoV) and, more recently, Middle East Respiratory Syndrome
Coronavirus (MERS-CoV), has raised awareness about the potential risks of highly virulent
coronavirus infections in humans with increasing close contact between humans and animals
harboring coronaviruses. However, effective therapeutic measures for coronavirus infections
have been elusive so far despite the extensive efforts in the development of anti-coronavirus
agents [4–8]. Shifts in tissue or cell tropism and resulting changes in virulence have also been
reported for coronaviruses; porcine respiratory coronavirus causes mild respiratory infection
in pigs and presumably arose from transmissible gastroenteritis virus (TGEV), the etiologic
agent of gastroenteritis in young pigs with a high fatality, by spontaneous mutations and/or
deletions in its genome [9]. Seemingly innocuous coronavirus infection can also be turned
deadly by changing its tropism, exemplified by mutation of feline enteric coronavirus (FECV)
to feline infectious peritonitis virus (FIPV) [10, 11]. Feline infectious peritonitis (FIP) has
intrigued researchers for half a century since its first description in the 1960s [10]. Infection
with FECV which causes inapparent or mild enteritis is widespread among cats, especially in
high-density environments, and has little clinical consequence. However, a small portion of
cats develop FIP during the course of FECV infection and succumb to the disease. Published
studies support that FIP arises in individual cats through mutation of the virus to gain tropism
for macrophages [12–16] and that the immune system of the infected cats plays an important
role in the pathogenesis of FIP [11]. FIP occurs in two major forms, effusive (wet) form or
non-effusive (dry) form. The wet form is more common (60–70% of FIP cases) and character-
ized by accumulation of fluids in the abdominal and/or, to a lesser degree, chest cavities [11].
Granulomatous vasculitis is frequently found in the omentum, mesenteric lymph nodes, and
serosal surface of the large intestine, resulting in the characteristic exudates rich in protein and
inflammatory cells in the body cavities in wet FIP [11]. The majority of exudate cells are virus-
infected macrophages and high virus load is detected in these cells [17]. Multiple
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granulomatous lesions composed of macrophages laden with viruses and other inflammatory
cells typically form in various tissues and organs, such as the omentum, mesenteric lymph
nodes, spleen and liver, in both forms of FIP [17]. Clinical symptoms of FIP reflect the organs
involved and include fever, jaundice, bodily effusions and weight loss and may also affect the
central nervous system and the eyes [11].
Virus-induced immunopathogenesis and lymphopenia in cats with FIP are features also fre-
quently associated with other coronavirus infections, such as SARS and MERS in humans. The
causes for lymphopenia observed in these coronavirus infections are not fully elucidated but
the published reports support that lymphopenia is related to the indirect effects of virus infec-
tion [18–20]. Lymphopenia associated with massive apoptosis of uninfected T-cells is a promi-
nent feature of both experimental and natural FIP [11, 17, 21, 22] and implicated with
cytokines secreted by the virus-infected macrophages and other immune cells [17, 19]. Lym-
phopenia precedes the onset of clinical signs and is associated with disease progression and
death in experimental FIP, which indicates that impaired cellular immune responses associated
with lymphocyte depletion is important in FIP pathogenesis [17, 22]. Once cats develop classic
clinical signs, fatality to FIP is virtually 100% [17, 23–25] and the median survival time from
the time of diagnosis to death or euthanasia is about 8–9 days [23, 24]. FIP is a leading cause of
death among young cats under 2 years of age and estimated to kill 1 in 100 to 300 cats world-
wide [10, 26]. FIP also affects endangered exotic cats in zoos, such as jaguars and cheetahs [27].
However, vaccines have proven ineffective and treatment is only palliative [25].
Studies of anti-coronavirus drugs have mainly focused on the discovery of anti-SARS-CoV
agents. Effective treatment intervention for coronavirus infections with an immunopathologi-
cal component, such as SARS, MERS and FIP, is speculated to involve the judicious use of
immunomodulatory agents to enhance protective host immunity and decrease pathological
immune responses and antiviral drugs to directly inhibit viral replication. We have previously
reported several series of small synthetic peptidyl compounds that target a virally-encoded pro-
tease, 3C-like protease (3CLpro) [28–30]. Coronavirus 3CLpro and papain-like protease (PLP)
process viral polyproteins into functional individual proteins and their structures are highly
conserved among coronaviruses. Since viral proteases are indispensable for virus replication,
many synthetic small molecules or natural compounds targeting 3CLpro or PLP of coronavi-
ruses have been investigated using the in vitro systems [4–8]. However, only few studies tested
the in vivo efficacy of protease inhibitors in experimental animals [30, 31]. Deng et at [31]
reported that a PLP inhibitor failed to reduce virus titers in the lung or increase the survival of
mice infected with a mouse-adapted SARS-CoV, presumably due to low bioavailability or sta-
bility of the inhibitor. Recently, we demonstrated that our 3CLpro inhibitors significantly
decreased the virus titers and pathology in the liver of mice infected with murine hepatitis
virus (MHV), a murine coronavirus [30]. In those studies, treatment was started shortly before
or after virus infection in asymptomatic mice.
Here we extended our previous work on coronavirus 3CLpro inhibitors and investigated the
pharmacokinetics (PK), safety and efficacy of a 3CLpro inhibitor in cats. GC376 is a 3CLpro
inhibitor which is previously reported to be active against the 3CLpro of multiple coronavi-
ruses, including SARS-CoV [28], but with highest potency against FIPV in cell culture. In this
study, we determined that GC376 exhibited favorable bioavailability and safety in cats. In the
in vivo efficacy study using GC376 in cats experimentally infected with FIPV, antiviral treat-
ment was started after the cats reached a clinical stage that would ultimately lead to death, if
untreated. Antiviral treatment caused a rapid reversal of clinical signs and lymphopenia and
reduction in viral titers in the macrophages from the ascites. Active infection was no longer
apparent after 14–20 days of antiviral treatment and the treated cats have remained normal
under observation for as long as eight months. These results provide important first evidence
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that a 3CLpro inhibitor is effective at reversing disease progression when administered to cats
in an advanced and invariably fatal stage of experimentally induced FIP.
Results
Pharmacokinetics study of GC376 in cats
GC376 (Fig 1) is a representative compound of the dipeptidyl transition state 3CLpro inhibi-
tors [28–30, 32] whose synthesis was described previously [28]. NPI64 shares homologous
structural elements with GC376, except that NPI64 has an additional residue of 1-naththylala-
nine compared to GC376 in a position that corresponds to the P3 position [30], using the
nomenclature of Schechter and Berger [33] (Fig 1). The comparable antiviral activity of GC376
and NPI64 against the replication of feline coronavirus in a cell culture system was previously
reported (Fig 1) [28, 30]. However, their PK properties have not been reported. In this study,
we investigated the drug plasma concentration changes in healthy specific pathogen free (SPF)
Fig 1. The chemical structures of 3CLpro inhibitors and their antiviral activity against feline
coronavirus in cell culture. The chemical structures of GC376 and NPI64 are shown. The 50% effective
concentration (EC50) values of GC376 or NPI64 against FIPV 3CLpro [28, 30] and the 50% cytotoxic
concentration (CC50) values of GC376 or NPI64 determined in various cell lines were previously reported [28,
30] and summarized in a table.
doi:10.1371/journal.ppat.1005531.g001
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cats of 6–9 month age (n = 2 for each compound) following single subcutaneous (s.c.) dose of
10 mg/kg GC376 or 5 mg/kg NPI64. Serial blood samples were then collected and the plasma
drug concentrations were measured. Previously, we reported that GC376 is converted into an
aldehyde form by the removal of the bisulfite group, and the aldehyde form forms a reversible
covalent bond with the nucleophilic cysteine residue of 3CLpro in the x-ray crystallography
studies [28]. We also observed the conversion of NPI64 into its aldehyde form in the blood.
Therefore the aldehyde forms of GC376 or NPI64 were measured in the plasma samples.
Fig 2A shows the plasma drug concentrations over time following single-dose administration
of GC376 (red triangles) or NPI64 (black circles). The PK study results indicate that GC376 is
rapidly absorbed after s.c. administration and the peak plasma level was reached within 2 hr
after injection. The mean plasma drug concentrations remained above the 50% effective con-
centration (EC50) value of the aldehyde form of GC376 (8 ng/ml) for 18 hrs post injection
(Fig 2A, red triangles). The plasma drug concentrations following injection of 5 mg/kg NPI64
stayed above the EC50 value of the aldehyde form of NPI64 (12 ng/ml) for 12 hrs post injection
(Fig 2A, black circles). The maximum detected plasma drug concentration following NPI64
administration was substantially lower than that of GC376 by 9.5-fold. This result indicate that
GC376 was more easily absorbed than NPI64 via the tested route, even when the lower dose of
NPI64 (5 mg/kg), compared to GC376 (10 mg/kg), was taken into account.
Four-week safety study of multiple doses of GC376 in cats
After the dosage regimen of GC376 was determined in the PK study, safety of GC376 was eval-
uated in four healthy SPF cats of 6–9 months of age. The cats were administered with 10 mg/kg
GC376 by s.c. injection twice daily at 9 AM and 5 PM for 4 weeks. For the duration of the
study, they were observed daily for adverse effects. Blood samples were taken weekly and the
complete blood counts and blood chemistry panels were conducted. During the study period,
Fig 2. Changes in plasma drug concentrations after administration of 3CLpro inhibitors via a subcutaneous route. (A) In the single-dose
pharmacokinetics study, two healthy specific pathogen free (SPF) cats were subcutaneously injected with GC376 at 10 mg/kg/dose or NPI64 at 5 mg/kg for
the determination of serial plasma drug concentrations. GC376 and NPI64 are readily converted into aldehyde forms in the blood [28]. The red triangles and
black circles indicate the plasma concentrations of the aldehyde forms of GC376 and NPI64, respectively (means and standard error of the means are
shown). (B) In the safety study, four healthy SPF cats were subcutaneously given GC376 at 10 mg/kg/dose daily at 9 AM and 5 PM for 4 weeks. During that
time, plasma drug concentrations were measured at 2 and 16 hr post-injection for the first three days and weekly thereafter (red and black triangles,
respectively, means are shown). The dotted red line indicates the EC50 value of GC376. The 50% cytotoxic concentration (CC50) value of GC376 (>150 μM)
is greater than the dotted blue line.
doi:10.1371/journal.ppat.1005531.g002
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there were no clinically significant changes in vital signs and clinical lab parameters (S1A–S1D
Fig), indicating that the dosage and the route of administration of GC376 was well-tolerated in
cats for the duration of the safety study.
During the safety study, additional blood samples were taken at 2 and 16 hr post drug
administration for the first three days and then weekly for 4 weeks. The plasma drug concen-
trations at 16 hr post administration were determined from the blood collected immediately
before next drug administration and thus represent the minimum drug levels in the plasma.
The results show that the lowest plasma drug concentrations remained above the EC50 value
(Fig 2B black triangles) and that the highest determined drug concentrations were well below
the CC50 value which is greater than 150 μM in cell culture [30] (Fig 2B red triangles). Based
on the results from the safety and the PK studies, the dose and administration route of GC376
was determined to be suitable for the in vivo efficacy study.
Experimental infection of cats with FIP and antiviral treatment
The experimental infection of cats with serotype I FIPV that induces wet FIP has been reported
previously [12, 17, 34]. FIPV is classified into serotypes I and II based on virus neutralization
tests. Serotype I FIPV is responsible for the majority (80–90%) of naturally-occurring FIP [10,
35–38]. In this experimental infection, an absolute lymphopenia, fever, weight loss, jaundice
and inapparent to mild ascites appear within 2–3 weeks after infection. Increasing jaundice
and ascites occur during the next 1–3 weeks. All the cats that develop lymphopenia and clinical
signs following experimental infection do not spontaneously recover but succumb to the dis-
ease [12, 17, 34].
To investigate the efficacy of GC376, we conducted two independent studies. In these stud-
ies, antiviral treatment was started after the infected cats developed the typical laboratory find-
ing of absolute lymphopenia and clinical symptoms to determine whether treatment with
GC376 is effective in reducing the severity of symptoms or fatality. In both studies, the infected
cats were monitored daily for fever, body weight, and outward disease signs and weekly for
lymphocyte counts. In the first efficacy study, four SPF cats of 8–10 months of age (P02, P03,
P07 and P10) were intraperitoneally administrated with a cat-passaged serotype I FIPV (FIPV-
m3c-2) [12, 17, 34]. Following infection, they developed lymphopenia and clinical symptoms
including inapparent or mild ascites within 14–20 days post infection (dpi) (Table 1). In the
Table 1. Clinical and laboratory findings in cats challenged with FIPV prior to antiviral treatment.
Clinical and laboratory ﬁndings prior to treatment
Cat Fever Weight
loss
Jaundice (mucous membrane or
plasma)
Ascites Lymphopenia (<676/
μl)
Treatment duration
(dpi)*
Outcome
P07 + + + Not
apparent
+ 20 days (15–34) Recovered
P10 + + + Not
apparent
+ 20 days (15–34) Recovered
P02 + + + Mild + 15 days (20–34) Recovered
P03 + + + Mild + 16 days (19–34) Recovered
P17 + + + Profound + 14 days (21–34) Recovered
P24 + + + Profound + 14 days (21–34) Recovered
P15 + + + Profound + 4 days (18–21) Euthanized
P16 + + + Profound + 7 days (18–24) Euthanized
* dpi, days post infection
doi:10.1371/journal.ppat.1005531.t001
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second study, the ascites of four SPF cats of 8–10 months of age inoculated with the same virus
(P15, P16, P17 and P24) were allowed to progress to more profound, classical abdominal effu-
sions, which closely resemble those of cats with naturally-occurring FIP frequently presented at
the clinics (Table 1). However, in order to alleviate suffering, the latter four cats were given
meloxicam, a non-steroidal anti-inflammatory drug, and subcutaneous fluids prior to antiviral
treatment. This supportive treatment was discontinued before antiviral drug treatment com-
menced. The eight cats from both studies developed jaundice, inapparent to profound ascites,
absolute lymphopenia (134~676/μl, reference range 1,200 to 8,000/μl) and high fever (up to
41.1°C) (Fig 3B and 3D, Table 1) before antiviral treatment was started. They also lost body
weight up to 13.6% of their pre-infection weight during this same period (Fig 3C). When they
reached this stage, twice daily s.c. administration of GC376 at 5–10 mg/kg/dose was started.
These cats were treated for 14–20 days, except for P15 and P16 that were euthanized after 4
and 7 days after starting antiviral treatment based on the severe nature of their clinical signs
(Fig 3A). All six remaining cats showed rapid improvement in attitude and resolution of fever
(Fig 3B). The profound absolute lymphopenia observed in all cats prior to antiviral treatment
also returned to normal before the next blood testing one week later (Fig 3D) and weight losses
were reversed and normal growth resumed (Fig 3C). Ascites and scrotal swelling indicative of
peritonitis also gradually resolved after a week of antiviral treatment. All cats that received anti-
viral treatment for 14–20 days appeared normal by clinical observation and laboratory testing.
The six recovered cats from both studies have remained healthy showing no signs of relapse
during an observation period up to 8 months. These experiments demonstrate that the protease
inhibitor was able to reverse disease progression when treatment was initiated at advanced clin-
ical stages of FIP.
Antiviral treatment significantly reduced viral load in the cats with FIP
Since FIPV is highly associated with tissues and is not reliably detected in blood at high levels
in cats with FIP [17], assessment of the efficacy of antiviral drugs in reducing the viral load
poses a difficulty in live animals. Although measuring virus titers of the exudate macrophages
from the ascites allows to determine the effects of antiviral drug against the replication of
FIPV, ascites rapidly decreased with antiviral treatment and we were not able to collect ascites
in the recovered cats. However, we determined the viral load in two cats from the second study
(P15 and P16) prior to and during antiviral treatment. These cats were euthanized after 4 and 7
days of antiviral treatment. On necropsy, both cats had severe pancreatitis, a possible complica-
tion of meloxicam treatment, but no lesions (P16) or mild lesions (P15) typical of FIP were
found. Virus titers in the macrophages from the ascites were determined by real-time quantita-
tive RT-PCR and the Ct values were analyzed by the comparative Ct method using the β-actin
as a reference gene [39]. The results showed that viral RNA level in the macrophages from the
ascites decreased commensurately with the duration of antiviral treatment in these cats. The
fold reduction of viral RNA level determined using the delta delta Ct method was 1,595.7 in
P15 that received 4 day-antiviral treatment (Fig 4A) and 171,755.9 in P16 that received 7 day-
antiviral treatment (Fig 4B), compared to the pre-treatment viral RNA level in the macro-
phages of each cat. The viral RNA levels (2-ΔCt) in the macrophages from the ascites are sum-
marized in Fig 4D. The viral RNA level in the omentum of P15 and P16 is also shown in
Fig 4C. Based on these results, the reduction in virus titers in P15 and P16 seems to correlate
with the necropsy findings of mild or no FIP lesions in those cats. These results on viral
titers show that FIPV 3CLpro is a valid target for FIPV antiviral drugs and GC376 can effec-
tively reduce the virus load in the macrophages from the ascites and the omentum of cats with
FIP.
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Comparison of in vitro selection of GC376 and NPI52-resistant FIPV
Serial passages of FIPV-1146 in Crandell Rees feline kidney (CRFK) cells in the presence of
GC376 or NPI52 (an aldehyde form of NPI64) were conducted to compare the emergence of
viral resistance under drug pressure. At passage number 10, the EC50 value of NPI52 against
FIPV increased by 15-fold, compared to wild-type virus at the same passage number. However,
a decrease in antiviral activity of GC376 against FIPV was not observed at up to 20 passages.
The sequence analysis of the 3CLpro gene of NPI52-resistant FIPV viruses collected from pas-
sage 10 revealed a single mutation of serine to cysteine at the position of 131, which is located
between the β-strands cII and dII in the domain II (S2A Fig). Since these compounds share
similar structure, we also investigated whether NPI52-resistant viruses retain susceptibility to
Fig 3. Antiviral treatment of symptomatic cats with FIP. (A) In two independent studies, cats were inoculated with FIPV at day 0 and GC376 treatment
was started after they developed lymphopenia and clinical symptoms. In the 2nd study, cats received supportive treatment for five days (shaded boxes),
which was discontinued prior to antiviral treatment. The arrows and forward slashes indicate antiviral treatment duration and euthanasia, respectively. dpi,
days post infection. (B-D) Responses of cats with FIP to antiviral treatment: body temperature (B), percent body weight changes (C) and lymphocyte counts
(D) over time. The shaded areas indicate the normal range of values. Colored arrows located between panels B and D indicate the treatment duration for
each cat.
doi:10.1371/journal.ppat.1005531.g003
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GC376. GC376 effectively inhibited the replication of NPI52-resistant viruses in cell culture as
wild-type viruses, indicating that the mutation does not confer cross-resistance to GC376.
The 3CLpro inhibitor, GC376, is active against 3CLpro of MERS-CoV
and SARS-CoV in a fluorescence resonance energy transfer (FRET)
assay
Coronavirus 3CLpro are highly conserved in their structure and the active site [28, 40, 41]. S2A
Fig shows the superimposed 3CLpro structures of MERS-CoV (PDB ID: 4WME, teal) [40] and
FIPV (red) modelled based on TGEV 3CLpro (PDB ID: 4F49) [28]. The 3CLpro of TGEV and
FIPV are highly conserved with the amino acid sequence identity of>93%. However, 3CLpro
of TGEV, MERS-CoV and SARS-CoV have low amino acid sequence identity of about 50%.
Nonetheless, they share well conserved overall structure (S2A Fig). The activity of GC376 was
previously reported against the 3CLpro of SARS-CoV using a FRET assay [28]. However, its
activity against the 3CLpro of MERS-CoV and FIPV is unknown. Therefore, we cloned and
expressed the full-length 3CLpro of FIPV and MERS-CoV following the procedures described
previously [28]. The results are summarized in Fig 5. The data show that GC376 was most
effective against FIPV 3CLpro by a FRET assay but it also substantially inhibited the activity of
MERS-CoV and SARS-CoV 3CLpro.
Discussion
Since FIP disease progression is quite rapid and the pathogenesis of FIP is primarily immune-
mediated, an important question has remained unanswered as to whether antiviral drug treat-
ment can effectively reverse disease progression in symptomatic hosts. It was previously shown
that anti-inflammatory agent or antiviral immunity enhancing agents increased survival of
Fig 4. Changes in the viral RNA levels in P15 and P16 before and during antiviral treatment. (A and B) The viral RNA fold changes in the macrophages
from the ascites of P15 (A) and P16 (B) over time are shown. The Ct values from viral RNA real-time qRT-PCRwere normalized to β-actin and the 2-ΔΔCt
method was used to calculate the relative change in viral RNA level, compared to the pre-treatment value. (C) The viral RNA level (2-ΔCt) in the omentum of
P15 and P16 which are collected after 4 and 7 days of antiviral treatment, respectively. The bar graph shows the 2-ΔCt values calculated by normalizing the Ct
values from viral RNA real-time qRT-PCR to β-actin. (D) The 2-ΔCt values for each viral RNA in the macrophages from the ascites of P15 and P16 at pre-
treatment and during treatment are listed in the table. N/A, not available.
doi:10.1371/journal.ppat.1005531.g004
Antiviral Therapy for Fatal Feline Coronavirus Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005531 March 30, 2016 9 / 18
mice infected with mouse-adapted SARS-CoV and treated with a NF-kB inhibitor [42] or vari-
ous toll-like receptor agonists [31, 42–44], which was started shortly before or after virus infec-
tion. These reports indicate that controlling immune responses may prove an effective
therapeutic strategy for coronavirus infections where inflammation plays an important role in
pathogenesis. However, the available data on the efficacy of antiviral compounds failed to show
sufficient effectiveness in mice infected with mouse-adapted SARS-CoV, even when treatment
was started at the same time or shortly after virus infection [31, 43]. The observed low effective-
ness of antiviral treatment is largely thought to be due to the use of compounds with weak anti-
coronavirus activity and/or bioavailability. However, the lack of available potent antiviral com-
pounds against coronaviruses has made it difficult to investigate the effects of antiviral treat-
ment in animals with lethal coronavirus infection. Our 3CLpro inhibitors were previously
reported to be potent against FIPV in the in vitro assays [28, 30] and effective at significantly
reducing viral titers and tissue pathology in mice infected with MHV [30]. However, these
3CLpro inhibitors have not been tested in cats. In this study, a 3CLpro inhibitor, GC376, was
determined to be safe with good bioavailability in cats. In the in vivo efficacy study using cats
with FIP, the antiviral treatment started for cats at clinically advanced stages led to rapid nor-
malization of the numbers of lymphocytes, during which time, fever, jaundice and ascites also
resolved. The granulomatous lesions typically found in various organs in the cats infected with
Fig 5. Activity of GC376 against 3CLpro of various coronaviruses in a fluorescence resonance energy
transfer (FRET) assay. The upper graph shows the percent activity of 3CLpro of FIPV, SARS-CoV, and
MERS-CoV in the presence of GC376, determined by a FRET assay. The lower table summarizes the 50%
inhibitory concentration (IC50) values of GC376 against 3CLpro of FIPV, SARS-CoV, and MERS-CoV.
Asterisks indicate the previously published value [28].
doi:10.1371/journal.ppat.1005531.g005
Antiviral Therapy for Fatal Feline Coronavirus Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005531 March 30, 2016 10 / 18
FIPV were not found or greatly reduced in the two cats that were euthanized after only 4 and 7
days of antiviral treatment. These results demonstrate that continuous virus replication is
important in the progression of the immune-mediated pathogenesis of FIP and that controlling
virus replication by a directly-acting antiviral compound targeting coronavirus 3CLpro is effec-
tive at reversing FIP disease. Our results provide the first evidence, to our best knowledge, that
a direct-acting antiviral agent is effective at reversing the immune-mediated disease progres-
sion caused by coronavirus infection, even when antiviral treatment was started at clinically
advanced stages. This finding may have important implication in devising effective therapeutic
strategies for other coronavirus infections.
The conserved active site of coronavirus 3CLpro has been considered as a promising target
for the design of broad-spectrum inhibitors for coronavirus infections [7, 45] and our group
[28] and others [8, 46, 47] have previously reported the synthesis of 3CLpro inhibitors with
antiviral activity against multiple coronaviruses. GC376 was previously shown to be active
against FIPV in cell culture [28, 30] and SARS-CoV 3CLpro in a FRET assay [28]. In this
study, we compared the activity of GC376 against the 3CLpro of FIPV, MERS-CoV and SARS--
CoV by a FRET assay and determined that GC376 has most potent activity against the 3CLpro
of FIPV. The IC50 values of GC376 against MERS-CoV and SARS-CoV were 2.16 and
4.87-fold, respectively, higher than that against FIPV in a FRET assay. These results indicate
that GC376 is active against the 3CLpro of coronaviruses belonging to alphacoronavirus
(FIPV) or the multiple clades in betacoronavirus (MERS-CoV and SARS-CoV), despite the low
sequence identity of 3CLpro among FIPV, SARS-CoV, and MERS-CoV. The varying degree of
effectiveness of GC376 against 3CLpro of different coronaviruses may reflect a subtle difference
in spatial structure fit of the compound in the active site of coronavirus 3CLpro (S2B and S2C
Fig). However, the antiviral activity of GC376 against the replication of these human coronavi-
ruses has not yet been determined in cell culture or in the animal models.
A majority of reported protease inhibitors that are shown to have inhibitory effects against
various coronaviruses in the enzyme assay are tripeptidyl or bulkier compounds [8, 48–51] and
their antiviral activities in cell culture or in vivo properties are often not available. In this study,
we compared the subcutaneous absorption of dipeptidyl and tripeptidyl 3CLpro inhibitors.
GC376, a dipeptidyl compound, consists of a warhead, a Gln surrogate structure in a position
that corresponds to the P1 position, Leu in the P2 position and a cap structure [28] (Fig 1).
NPI64, a tripeptidyl compound, has homologous structural elements with GC376, except that
NPI52 has an additional residue of 1-naththylalanine (Fig 1). These two compounds have com-
parable antiviral activity against FIPV in cell culture (Fig 1) [30]. However, the peak plasma
concentration following a subcutaneous injection of NPI64 was considerably lower than that of
GC376, which indicates that GC376 is absorbed better than NPI64 via the subcutaneous route.
Our results on these closely related compounds indicate that relatively small structural change
(addition of a residue) can have profound effects in absorption, and therefore the bioavailabil-
ity of compounds needs to be taken into consideration early during drug selection process.
GC376 was also found to be well-tolerated in cats during the 4-week duration of twice daily
administration, with plasma drug concentrations remaining above the EC50 value but well
below the CC50 value.
Emergence of viral resistance is a major concern in antiviral therapy. The only available lit-
erature on protease inhibitor-resistant coronavirus [52] reported that a 3CLpro inhibitor
(GRL-001) has a low genetic barrier to MHV. In that study, resistant viruses were selected in 4
passage numbers in the presence of the inhibitor in cell culture, but the resistant viruses were
highly attenuated in mice. To study the development of viral resistance against our 3CLpro
inhibitors, we serially passaged FIPV in the presence of mock (vehicle), GC376 or the aldehyde
form (NPI52) of NPI64. At passage 10, the EC50 value of NPI52 increased by 15-fold,
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compared to wild-type viruses passaged without NPI52, indicating the emergence of NPI52-re-
sistant viruses. The 3CLpro gene of NPI52-resistant virus has a single mutation of S131C
which located between the cII and dII strands in the domain II (S2A Fig). The role of this
mutation in the 3CLpro in conferring resistance to NPI52 is currently not clear. However, the
fact that serine at this position is conserved among all feline coronaviruses whose sequences
are available and that C144, the active site residue that forms a covalent bond with the warhead
of the inhibitor, is on the same loop as S131 between the cII and dII strands (S2A Fig) suggest
that this mutation may influence the conformation of the loop and positioning of the active-
site residue for proteolysis. Interestingly, Deng et al [52] also reported that one of the mutations
on 3CLpro of MHV which is partially resistant to GRL-001 is located away from the catalytic
site but in a position that may influence the conformation of the catalytic site. In contrast to
NPI52, resistant viruses against GC376 have not been selected at up to 20 passages. These
results indicate that similarly structured compounds may have different levels of resistance bar-
rier against coronavirus 3CLpro. Interestingly, NPI52-resistant viruses did not lose susceptibil-
ity to GC376 in cell culture, indicating that this mutation did not confer cross-resistance. The
mechanisms underlying differences in resistance development to these inhibitors need to be
defined, but it may be speculated that the small size of GC376, compared to NPI52, makes it
difficult for the virus to evade drug binding while retaining substrate cleavage capability. We
are currently investigating the relative viral fitness of the resistant viruses and the role of the
mutation in conferring resistance to NPI52.
In summary, a representative compound, GC376, of our dipeptidyl 3CLpro inhibitor series
was shown to be safe by the dosage regimen used in cats and effective at reversing the progres-
sion of FIP even when the treatment was started at advanced clinical stages. Based on these
results, this compound may have the potential to be developed into a safe and effective drug for
FIP. Furthermore, broad activity of this compound against important human coronaviruses,
including MERS-CoV and SARS-CoV, suggest that our inhibitor series may serve as a platform
for further optimization for those important viruses. The results of this study also suggest that
similar intervention approaches targeting virally-encoded 3CLpro warrant investigation for
other existing and emerging coronavirus infections.
Materials and Methods
Experimental cats
Random bred cats free of most common feline pathogens, including feline enteric coronavirus,
were obtained from the feline nutrition breeding colony, School of Veterinary Medicine, UC
Davis.
Ethics statement
All animal experiments were conducted in strict compliance with the Animal Welfare Act,
PHS Policy and other federal statutes and regulations relating to animals and approved by the
Institutional Animal Care and Use Committee at University of California, Davis (Protocol
Number:17557).
Synthesis of GC376
The syntheses of GC376 and NPI64 were previously described by our group [28, 53].
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PK and safety studies
In the single-dose PK study, two healthy SPF cats of 6–9 months of age (n = 2 for each com-
pound) were subcutaneously injected with 10 mg/kg GC376 or 5 mg/kg NPI64 dissolved in
10% EtOH and 90% PEG400. Blood samples were collected from each cat at 2, 6, 12, 18, 24, 30,
and 48 hrs following injection and plasma samples were prepared. The plasma drug concentra-
tions were measured using routine high pressure liquid chromatography by Frontage Laborato-
ries, Inc (Exton, PA). In the safety (multiple-dose) study, four healthy SPF cats of 6–9 months
of age were injected s.c. with a daily dose of GC376 (10 mg/kg/dose dissolved in 10% EtOH,
50% PEG400 and 40% PBS) at 9AM and 5 PM for 4 weeks. Plasma samples were prepared for
determination of drug concentrations at 2 or 16 hrs (immediately before the next dose) after
drug administration for the first three days and weekly thereafter for 4 weeks. Measurement of
plasma drug concentrations from the safety study was also performed by Frontage Laborato-
ries, Inc. During the safety study, cats were monitored twice daily for adverse effects and body
weight was measured daily. Prior to the first dose of GC376 and thereafter weekly, blood sam-
ples were collected from each cat for complete blood count and blood chemistry tests.
In vivo efficacy study
A total of eight female or male SPF cats of 8–10 months of age in two independently conducted
studies were originally part of another published experiment concerning the role of genetics in
susceptibility/resistance to FIPV infection [54]. In that study, cats were inoculated with cat-
passaged serotype I field strain FIPV-m3c-2. Among the cats that developed clinical and labo-
ratory signs consistent with the abdominal effusive (wet) form of FIP and progressed to the
point where they would be inevitably fatal, eight cats were transferred to the drug efficacy
study. Four cats (P02, P03, P07 and P10) in the first study did not receive any medication other
than GC376. Five doses of oral or subcutaneous meloxicam at 0.3 mg/kg/dose (once a day) as
well as fluids were given to four cats (P15, P16, P17 and P24) in the second study for alleviation
of pain and dehydration and discontinued before antiviral treatment was started. GC376 dis-
solved in 10% EtOH, 50% PEG400 and 40% PBS was given s.c. at 9 AM and 5 PM for 14–20
days. P03 and P07 were given GC376 at 5 mg/kg/dose for 4 or 8 days, respectively, and the
dose was increased to 10 mg/kg/dose until the end of antiviral treatment. P15 and P16 were
euthanized following antiviral treatment of 4 and 7 days, respectively. All other cats received
GC376 at 10 mg/kg/dose during antiviral treatment. Animals were observed daily for clinical
signs and body weight and blood was collected weekly for lymphocyte counts. Ascites were col-
lected at multiple times before and during antiviral treatment from P15 and P16 for virus titra-
tion by real-time quantitative RT-PCR (qRT-PCR). The omentum samples were collected from
P15 and p16 on necropsy.
Virus quantitation by real-time qRT-PCR
Virus titers in the macrophages from the ascites and the omentum were determined by real-
time qRT-PCR. Ascites (1 ml) collected from P15 and P16 were diluted at 1:5 in PBS contain-
ing 10 units/ml heparin. After centrifugation, the cell pellets were incubated with 500 μl RNA-
later (Life Technologies, NY, USA) for overnight at 4°C. Cell pellets were then collected by
centrifugation and stored at -20°C until analysis. Prior to total RNA extraction, 200 μl of PBS
was added to the cell pellets. Omentum was cut into a size of less than 0.5 cm and placed in 5
volumes of RNAlater. Following overnight incubation at 4°C, samples were centrifuged for 5
min at 13,000 rpm to remove supernatant and tissues were stored at -70°C until analysis. Total
RNA was extracted from the macrophages from the ascites and the omentum using RNeasy
mini kit (Life Technologies) and real-time qRT-PCR was conducted. The primers and a probe
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targeting the 3’-UTR region of FIPV are 5’-GGAGGTACAAGCAACCCTATT-3’ (a forward
primer), 5’-GATCCAGACGTTAGCT CTTCC-3’ (a reverse primer) and FAM-AGATCCGC
TATGACGAGCCAACAA-Iowa Black (a probe). The relative levels of viral RNA in the sam-
ples were calculated by the comparative Ct method [39] using beta actin as a reference gene.
The fold changes in viral RNA level in the macrophages in the ascites collected during antiviral
treatment were calculated using the viral RNA level in the macrophage samples collected prior
to the antiviral treatment.
Serial passages of FIPV to generate viruses resistant to GC376 and
NPI52
Sequential in vitro passage experiments using wild-type FIPV-1146 in the presence of GC376
or NPI52 were performed to select resistant viruses. Briefly, CRFK cells were infected with
FIPV at an MOI of 0.05–1 in the presence of GC376 or NPI52 ranging from 0.5~3 μM. At each
passage, supernatants containing viruses were passed on to fresh cells in the presence of GC376
or NPI52. Control mock virus was passaged in the absence of drug following the same proce-
dure. Virus titers at certain passage numbers were determined by the 50% tissue culture infec-
tive dose assay and the fold changes in EC50 values relative to the wild-type virus were
determined. After 10 passages in the presence or absence of NPI52, total viral RNA was isolated
using the RNeasy Mini kit (Invitrogen) and the 3CLpro gene was sequenced following amplifi-
cation by RT-PCR and analyzed for the presence of mutations. The viruses grown without the
drug (mock) or NPI52-resistant viruses at passage number 10 were purified three times by lim-
iting dilution [55].
To investigate if NPI52-resistant viruses are susceptible to GC376, serial dilutions of GC376
or NPI52 were added to confluent monolayers of CRFK cells in 24-well plates or cells were
mock-treated, and the cells were immediately infected with NPI52-resistant virus at an MOI of
0.05–1. Following incubation at 37°C until an extensive cytopathic effect was observed in the
mock-treated well (up to 36 hrs), cells were freeze-thawed for virus titration. The EC50 values
were determined using Graphpad Prism software version 6 (GraphPad Software, San Diego,
CA) following the procedures described previously [28, 30].
Expression of 3CLpro
The codon-optimized cDNA encoding the full length 3CLpro of FIPV-m3c-2 was amplified by
RT-PCR using the omentum tissue from the cats infected with FIPV-m3c-2. Those of SARS--
CoV (GenBank: GU553365.1) and MERS-CoV (GenBank: KM210277) were synthesized by
GenScript (Piscataway, NJ). The expression and purification of each 3CLpro were conducted
following a standard method described previously by our group [28]. Primers for MERS
3CLpro are; forward primer (ATTCTAGAAAGGAGATATACCATGCAT CATCATCAT
CATCATAGCGGTCTGGTTAAAATGAGCC) and reverse primer (ATCTCGAGTCACTG
CATCACAACACCCATAATC). Primers for FIPV 3CLpro are; forward primer (ATTCTA
GAAAGGAGATATACCATGCATCATCATCATCATCATTCTG GATTGC
GAAAAATGGC) and reverse primer (ATCTCGAGGCGGCCGCTCACTGACT).
FRET assay
FRET assay was performed using a fluorogenic substrate (dabcyl-KTSAVLQ/SGFRKME-
edans) derived from the cleavage sites on viral polyproteins of SARS-CoV [28] and was synthe-
sized by GenScript. Methods for FRET assay were described previously by our group [28, 30].
Briefly, in the FRET assay, 3CLpro of FIPV, MERS-CoV, or SARS-CoV were incubated with
GC376 for 30 min and the edans/dabcyl FRET substrate derived from the cleavage sites on
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SARS-CoV polyprotein was added to the mixture. Following incubation for 30 min, the flores-
cence signals were measured and the IC50 was calculated for each 3CLpro [28–30].
Three-dimensional structural model of 3CLpro
The structural model of FIPV 3CLpro was built based on TGEV 3CLpro (PDB ID: 4F49) [28]
using the EasyModeller program (version 4.0) [56] and superimposed on the 3CLpro structure
of MERS-CoV (PDB ID: 4WME, teal) [40]. The surface representation of the active sites of
TGEV (PDB ID: 4F49) and MERS-CoV (PDB ID: 4WME) were created with PyMol (DeLano
Scientific) [57].
Supporting Information
S1 Fig. Body weight and blood cell counts and blood chemistry measurements in cats sub-
cutaneously administered with GC376 in the safety study. (A) Body weights of cats over
time. (B-D) Various blood chemistry values or blood cell counts over time are expressed as
means and standard error of the means. AP, alkaline phosphatase. BUN, blood urea nitrogen.
ALT, alanine aminotransferase. AST, aspartate aminotransferase. ALP, alkaline phosphatase.
Hg, hemoglobin.
(TIF)
S2 Fig. Three-dimensional structural model of FIPV 3CLpro and surface representation of
the active site of 3CLpro of TGEV and MERS-CoV. (A) Superimposition of MERS-CoV
3CLpro (PDB ID: 4WME, teal) [40] and FIPV 3CLpro (red) modeled using Modeller [56]
based on TGEV 3CLpro as a template (PDB ID: 4F49) [28]. The 3CLpro of TGEV and FIPV
are highly conserved with the amino acid sequence identity of>93%. Coronavirus 3CLpro
forms a dimer for function but only the monomer form is shown here. The tan rectangle con-
tains the active site located in the cleft between the domains I and II. The active site residues of
3CLpro of MERS-CoV and FIPV, Cys and His, are shown in orange and blue colors, respec-
tively. The residue (S131) mutated in the 3CLpro of FIPV resistant to NPI52, an aldehyde form
of NPI64, is shown in purple. (B and C) Surface representation of the active sites of 3CLpro of
TGEV (PDB ID: 4F49)[28](C) and MERS-CoV (PDB ID: 4WME)[40](D). (B) The crystal
structure of TGEV 3CLpro bound with GC376 (gray) in the S1 and S2 pockets of the active site
of 3CLpro was previously published by our group [28]. The residues in the S1 and S2 pockets
that form hydrogen bonds with GC376 are shown in yellow. (C) The S1 and S2 pockets of
MERS-CoV 3CLpro are shown in pink. The residues that can potentially form hydrogen bonds
with GC376 are indicated. All images were newly prepared using PyMol.
(TIF)
Acknowledgments
We thank Monica Durden for care of cats and David George for technical assistance.
Author Contributions
Conceived and designed the experiments: YK KOC NCPWCG. Performed the experiments:
HL ACGK SW. Analyzed the data: YK KOC NCP. Contributed reagents/materials/analysis
tools: YK KOCWCG DHHNCP. Wrote the paper: YK NCP.
References
1. King AM, Lefkowitz E, Adams MJ, Carstens EB, editors. Virus Taxonomy: Ninth Report of the Interna-
tional Committee on Taxonomy of Viruses 1ed: Elsevier; 2011.
Antiviral Therapy for Fatal Feline Coronavirus Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005531 March 30, 2016 15 / 18
2. Lai MM, Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res. 1997; 48:1–100. PMID:
9233431.
3. Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, et al. Discovery of seven novel Mammalian and
avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of
alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacorona-
virus and deltacoronavirus. J Virol. 2012; 86(7):3995–4008. Epub 2012/01/27. doi: 10.1128/JVI.06540-
11 [pii]. PMID: 22278237; PubMed Central PMCID: PMCPMC3302495.
4. Adedeji AO, Sarafianos SG. Antiviral drugs specific for coronaviruses in preclinical development. Curr
Opin Virol. 2014; 8:45–53. doi: 10.1016/j.coviro.2014.06.002 PMID: 24997250; PubMed Central
PMCID: PMCPMC4195804.
5. Kumar V, Jung YS, Liang PH. Anti-SARS coronavirus agents: a patent review (2008—present). Expert
Opin Ther Pat. 2013; 23(10):1337–48. doi: 10.1517/13543776.2013.823159 PMID: 23905913.
6. De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert
Rev Anti Infect Ther. 2006; 4(2):291–302. Epub 2006/04/07. doi: 10.1586/14787210.4.2.291 PMID:
16597209.
7. Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral
drug design. FEBS J. 2014; 281(18):4085–96. doi: 10.1111/febs.12936 PMID: 25039866.
8. Yang H, Xie W, Xue X, Yang K, Ma J, LiangW, et al. Design of wide-spectrum inhibitors targeting coro-
navirus main proteases. PLoS Biol. 2005; 3(10):e324. Epub 2005/09/01. 05-PLBI-RA-0435R1 [pii] doi:
10.1371/journal.pbio.0030324 PMID: 16128623; PubMed Central PMCID: PMCPMC1197287.
9. Rasschaert D, Duarte M, Laude H. Porcine respiratory coronavirus differs from transmissible gastroen-
teritis virus by a few genomic deletions. J Gen Virol. 1990; 71 (Pt 11):2599–607. PMID: 2174956.
10. Pedersen NC. A review of feline infectious peritonitis virus infection: 1963–2008. J Feline Med Surg.
2009; 11(4):225–58. Epub 2009/03/04. doi: 10.1016/j.jfms.2008.09.008 S1098-612X(09)00017-5 [pii].
PMID: 19254859.
11. Pedersen NC. An update on feline infectious peritonitis: Virology and immunopathogenesis. Veterinary
Journal. 2014; 201(2):123–32. doi: 10.1016/j.tvjl.2014.04.017WOS:000340225200002.
12. Pedersen NC, Liu H, Scarlett J, Leutenegger CM, Golovko L, Kennedy H, et al. Feline infectious perito-
nitis: role of the feline coronavirus 3c gene in intestinal tropism and pathogenicity based upon isolates
from resident and adopted shelter cats. Virus Res. 2012; 165(1):17–28. Epub 2012/01/28. doi: 10.
1016/j.virusres.2011.12.020 PMID: 22280883.
13. Pedersen NC, Liu H, Dodd KA, Pesavento PA. Significance of coronavirus mutants in feces and dis-
eased tissues of cats suffering from feline infectious peritonitis. Viruses. 2009; 1(2):166–84. doi: 10.
3390/v1020166 PMID: 21994544; PubMed Central PMCID: PMCPMC3185486.
14. Chang HW, Egberink HF, Halpin R, Spiro DJ, Rottier PJ. Spike protein fusion Peptide and feline coro-
navirus virulence. Emerg Infect Dis. 2012; 18(7):1089–95. Epub 2012/06/20. doi: 10.3201/eid1807.
120143 PMID: 22709821; PubMed Central PMCID: PMCPMC3376813.
15. Barker EN, Tasker S, Gruffydd-Jones TJ, Tuplin CK, Burton K, Porter E, et al. Phylogenetic analysis of
feline coronavirus strains in an epizootic outbreak of feline infectious peritonitis. J Vet Intern Med. 2013;
27(3):445–50. doi: 10.1111/jvim.12058 PMID: 23517431.
16. Licitra BN, Millet JK, Regan AD, Hamilton BS, Rinaldi VD, Duhamel GE, et al. Mutation in spike protein
cleavage site and pathogenesis of feline coronavirus. Emerg Infect Dis. 2013; 19(7):1066–73. doi: 10.
3201/eid1907.121094 PMID: 23763835; PubMed Central PMCID: PMCPMC3713968.
17. Pedersen NC, Eckstrand C, Liu H, Leutenegger C, Murphy B. Levels of feline infectious peritonitis virus in
blood, effusions, and various tissues and the role of lymphopenia in disease outcome following experimen-
tal infection. Vet Microbiol. 2015; 175(2–4):157–66. doi: 10.1016/j.vetmic.2014.10.025 PMID: 25532961.
18. Chan PK, Chen GG. Mechanisms of lymphocyte loss in SARS coronavirus infection. Hong Kong Med
J. 2008; 14 Suppl 4:21–6. PMID: 18708670.
19. Takano T, Hohdatsu T, Hashida Y, Kaneko Y, Tanabe M, Koyama H. A "possible" involvement of TNF-
alpha in apoptosis induction in peripheral blood lymphocytes of cats with feline infectious peritonitis.
Vet Microbiol. 2007; 119(2–4):121–31. Epub 2006/10/19. S0378-1135(06)00357-9 [pii] doi: 10.1016/j.
vetmic.2006.08.033 PMID: 17046178.
20. Takano T, Hohdatsu T, Toda A, Tanabe M, Koyama H. TNF-alpha, produced by feline infectious perito-
nitis virus (FIPV)-infected macrophages, upregulates expression of type II FIPV receptor feline amino-
peptidase N in feline macrophages. Virology. 2007; 364(1):64–72. Epub 2007/03/27. S0042-6822(07)
00119-5 [pii] doi: 10.1016/j.virol.2007.02.006 PMID: 17382365.
21. Dean GA, Olivry T, Stanton C, Pedersen NC. In vivo cytokine response to experimental feline infectious
peritonitis virus infection. Vet Microbiol. 2003; 97(1–2):1–12. Epub 2003/11/26. S0378113503002918
[pii]. PMID: 14637034.
Antiviral Therapy for Fatal Feline Coronavirus Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005531 March 30, 2016 16 / 18
22. de Groot-Mijnes JD, van Dun JM, van der Most RG, de Groot RJ. Natural history of a recurrent feline
coronavirus infection and the role of cellular immunity in survival and disease. J Virol. 2005; 79
(2):1036–44. Epub 2004/12/23. 79/2/1036 [pii] doi: 10.1128/JVI.79.2.1036-1044.2005 PMID:
15613332; PubMed Central PMCID: PMCPMC538555.
23. Ritz S, Egberink H, Hartmann K. Effect of feline interferon-omega on the survival time and quality of life
of cats with feline infectious peritonitis. J Vet Intern Med. 2007; 21(6):1193–7. Epub 2008/01/17. PMID:
18196725.
24. Fischer Y, Ritz S, Weber K, Sauter-Louis C, Hartmann K. Randomized, placebo controlled study of the
effect of propentofylline on survival time and quality of life of cats with feline infectious peritonitis. J Vet
Intern Med. 2011; 25(6):1270–6. Epub 2011/11/19. doi: 10.1111/j.1939-1676.2011.00806.x PMID:
22092616.
25. Pedersen NC. An update on feline infectious peritonitis: Diagnostics and therapeutics. Veterinary Jour-
nal. 2014; 201(2):133–41. doi: 10.1016/j.tvjl.2014.04.016WOS:000340225200003.
26. Rohrbach BW, Legendre AM, Baldwin CA, Lein DH, ReedWM,Wilson RB. Epidemiology of feline
infectious peritonitis among cats examined at veterinary medical teaching hospitals. J Am Vet Med
Assoc. 2001; 218(7):1111–5. Epub 2001/04/25. PMID: 11318361.
27. Heeney JL, Evermann JF, McKeirnan AJ, Marker-Kraus L, Roelke ME, Bush M, et al. Prevalence and
implications of feline coronavirus infections of captive and free-ranging cheetahs (Acinonyx jubatus). J
Virol. 1990; 64(5):1964–72. Epub 1990/05/01. PMID: 2157864; PubMed Central PMCID:
PMCPMC249350.
28. Kim Y, Lovell S, Tiew KC, Mandadapu SR, Alliston KR, Battaile KP, et al. Broad-spectrum antivirals
against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol. 2012; 86
(21):11754–62. Epub 2012/08/24. JVI.01348-12 [pii] doi: 10.1128/JVI.01348-12 PMID: 22915796.
29. Kim Y, Mandadapu SR, Groutas WC, Chang KO. Potent inhibition of feline coronaviruses with peptidyl
compounds targeting coronavirus 3C-like protease. Antiviral Res. 2013; 97(2):161–8. Epub 2012/12/
12. S0166-3542(12)00260-4 [pii] doi: 10.1016/j.antiviral.2012.11.005 PMID: 23219425.
30. Kim Y, Shivanna V, Narayanan S, Prior AM, Weerasekara S, Hua DH, et al. Broad-spectrum inhibitors
against 3C-Like proteases of feline coronaviruses and feline caliciviruses. J Virol. 2015; 89(9):4942–
50. Epub 2015/02/20. doi: 10.1128/JVI.03688-14 PMID: 25694593.
31. Deng X, Agnihothram S, Mielech AM, Nichols DB, Wilson MW, StJohn SE, et al. A chimeric virus-
mouse model system for evaluating the function and inhibition of papain-like proteases of emerging
coronaviruses. J Virol. 2014; 88(20):11825–33. doi: 10.1128/JVI.01749-14 PMID: 25100850; PubMed
Central PMCID: PMCPMC4178736.
32. Chang KO, Takahashi D, Prakash O, Kim Y. Characterization and inhibition of norovirus proteases of
genogroups I and II using a fluorescence resonance energy transfer assay. Virology. 2012; 423
(2):125–33. Epub 2011/12/28. S0042-6822(11)00559-9 [pii] doi: 10.1016/j.virol.2011.12.002 PMID:
22200497.
33. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Com-
mun. 1967; 27(2):157–62. Epub 1967/04/20. S0006-291X(67)80055-X [pii]. PMID: 6035483.
34. Pedersen NC, Liu H, Gandolfi B, Lyons LA. The influence of age and genetics on natural resistance to
experimentally induced feline infectious peritonitis. Vet Immunol Immunopathol. 2014; 162(1–2):33–40.
doi: 10.1016/j.vetimm.2014.09.001 PMID: 25265870.
35. Wang YT, Chueh LL, Wan CH. An eight-year epidemiologic study based on baculovirus-expressed
type-specific spike proteins for the differentiation of type I and II feline coronavirus infections. BMC Vet
Res. 2014; 10:186.doi: 10.1186/s12917-014-0186-7 PMID: 25123112; PubMed Central PMCID:
PMCPMC4236817.
36. KummrowM, Meli ML, Haessig M, Goenczi E, Poland A, Pedersen NC, et al. Feline coronavirus sero-
types 1 and 2: seroprevalence and association with disease in Switzerland. Clin Diagn Lab Immunol.
2005; 12(10):1209–15. Epub 2005/10/08. 12/10/1209 [pii] doi: 10.1128/CDLI.12.10.1209-1215.2005
PMID: 16210485; PubMed Central PMCID: PMCPMC1247821.
37. Benetka V, Kubber-Heiss A, Kolodziejek J, Nowotny N, Hofmann-Parisot M, Mostl K. Prevalence of
feline coronavirus types I and II in cats with histopathologically verified feline infectious peritonitis. Vet
Microbiol. 2004; 99(1):31–42. Epub 2004/03/17. doi: 10.1016/j.vetmic.2003.07.010
S0378113503003821 [pii]. PMID: 15019109.
38. Hohdatsu T, Okada S, Ishizuka Y, Yamada H, Koyama H. The prevalence of types I and II feline coro-
navirus infections in cats. J Vet Med Sci. 1992; 54(3):557–62. Epub 1992/06/01. PMID: 1322718.
39. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc.
2008; 3(6):1101–8. PMID: 18546601.
40. Needle D, Lountos GT, Waugh DS. Structures of the Middle East respiratory syndrome coronavirus
3C-like protease reveal insights into substrate specificity. Acta Crystallogr D Biol Crystallogr. 2015; 71
Antiviral Therapy for Fatal Feline Coronavirus Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005531 March 30, 2016 17 / 18
(Pt 5):1102–11. doi: 10.1107/S1399004715003521 PMID: 25945576; PubMed Central PMCID:
PMCPMC4427198.
41. Shimamoto Y, Hattori Y, Kobayashi K, Teruya K, Sanjoh A, Nakagawa A, et al. Fused-ring structure of
decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors. Bioorg Med Chem. 2015;
23(4):876–90. doi: 10.1016/j.bmc.2014.12.028 PMID: 25614110.
42. DeDiego ML, Nieto-Torres JL, Regla-Nava JA, Jimenez-Guardeno JM, Fernandez-Delgado R, Fett C,
et al. Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavi-
rus-infected mice increases survival. J Virol. 2014; 88(2):913–24. doi: 10.1128/JVI.02576-13 PMID:
24198408; PubMed Central PMCID: PMCPMC3911641.
43. Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, et al. A newmouse-adapted strain of
SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology. 2009; 395
(2):210–22. Epub 2009/10/27. S0042-6822(09)00583-2 [pii] doi: 10.1016/j.virol.2009.09.023 PMID:
19853271.
44. Zhao J, Wohlford-Lenane C, Zhao J, Fleming E, Lane TE, McCray PB Jr., et al. Intranasal treatment
with poly(I*C) protects aged mice from lethal respiratory virus infections. J Virol. 2012; 86(21):11416–
24. doi: 10.1128/JVI.01410-12 PMID: 22915814; PubMed Central PMCID: PMCPMC3486278.
45. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro)
structure: basis for design of anti-SARS drugs. Science. 2003; 300(5626):1763–7. Epub 2003/05/15.
doi: 10.1126/science.1085658 1085658 [pii]. PMID: 12746549.
46. Ghosh AK, Gong G, Grum-Tokars V, Mulhearn DC, Baker SC, Coughlin M, et al. Design, synthesis and
antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors. Bioorg
Med Chem Lett. 2008; 18(20):5684–8. Epub 2008/09/18. doi: 10.1016/j.bmcl.2008.08.082 S0960-
894X(08)00986-4 [pii]. PMID: 18796354; PubMed Central PMCID: PMCPMC2745596.
47. Lee CC, Kuo CJ, Ko TP, Hsu MF, Tsui YC, Chang SC, et al. Structural basis of inhibition specificities of
3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds. J Biol Chem. 2009;
284(12):7646–55. Epub 2009/01/16. M807947200 [pii] doi: 10.1074/jbc.M807947200 PMID:
19144641; PubMed Central PMCID: PMC2658058.
48. Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, et al. The crystal structures of severe acute respiratory
syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A. 2003; 100
(23):13190–5. Epub 2003/10/31. doi: 10.1073/pnas.1835675100 1835675100 [pii]. PMID: 14585926.
49. Liang PH. Characterization and inhibition of SARS-coronavirus main protease. Curr Top Med Chem.
2006; 6(4):361–76. Epub 2006/04/14. PMID: 16611148.
50. Kuo CJ, Liu HG, Lo YK, Seong CM, Lee KI, Jung YS, et al. Individual and common inhibitors of corona-
virus and picornavirus main proteases. FEBS Lett. 2009; 583(3):549–55. Epub 2009/01/27. S0014-
5793(09)00016-7 [pii] doi: 10.1016/j.febslet.2008.12.059 PMID: 19166843.
51. Yang S, Chen SJ, Hsu MF, Wu JD, Tseng CTK, Liu YF, et al. Synthesis, crystal structure, structure-
activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. Journal
of Medicinal Chemistry. 2006; 49(16):4971–80. doi: 10.1021/jm0603926WOS:000239459800021.
PMID: 16884309
52. Deng X, StJohn SE, Osswald HL, O'Brien A, Banach BS, Sleeman K, et al. Coronaviruses resistant to
a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic bar-
rier but high fitness cost of resistance. J Virol. 2014; 88(20):11886–98. Epub 2014/08/08. doi: 10.1128/
JVI.01528-14 JVI.01528-14 [pii]. PMID: 25100843; PubMed Central PMCID: PMCPMC4178758.
53. Prior AM, Kim Y, Weerasekara S, Moroze M, Alliston KR, Uy RA, et al. Design, synthesis, and bioeva-
luation of viral 3C and 3C-like protease inhibitors. Bioorg Med Chem Lett. 2013; 23(23):6317–20. Epub
2013/10/16. doi: 10.1016/j.bmcl.2013.09.070 S0960-894X(13)01144-X [pii]. PMID: 24125888; PubMed
Central PMCID: PMCPMC3863581.
54. Pedersen NC, Liu H, Durden M, Lyons LA. Natural resistance to experimental feline infectious peritoni-
tis virus infection is decreased rather than increased by positive genetic selection. Veterinary Immunol-
ogy and Immunopathology. 2016; 171:17–20. doi: 10.1016/j.vetimm.2016.01.002 PMID: 26964713
55. Beaucourt S, Bordera AV, Coffey LL, Gnadig NF, Sanz-Ramos M, Beeharry Y, et al. Isolation of Fidelity
Variants of RNA Viruses and Characterization of Virus Mutation Frequency. Jove-J Vis Exp. 2011;
(52: ). UNSP e2953 doi: 10.3791/2953WOS:000209214900044.
56. Kuntal BK, Aparoy P, Reddanna P. EasyModeller: A graphical interface to MODELLER. BMC Res
Notes. 2010; 3:226. Epub 2010/08/18. doi: 10.1186/1756-0500-3-226 1756-0500-3-226 [pii]. PMID:
20712861; PubMed Central PMCID: PMCPMC2936912.
57. The PyMOLMolecular Graphics System VS, LLC.
Antiviral Therapy for Fatal Feline Coronavirus Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005531 March 30, 2016 18 / 18
